ASweetLife Team, Author at ASweetLife

Blood Pressure Drug Reduces Risk Of Cardiovascular Disease and Stroke

According to a press release by the AHA, a new study published in Hypertension: Journal of the American Heart Association has shown that a long-acting ACE inhibitor used to reduce blood pressure significantly decreased the risk for cardiovascular disease, including stroke, in normal weight, overweight and obese patients....

Increase in Diabetes and Obesity Linked to Sugary Drinks

A new study, reported by the American Heart Association...

FDA Tells Food Companies to Correct Labeling Violations

The U.S. Food and Drug Administration(FDA) has notified 17 food manufacturers that the labeling for 22 of their food products violates the Federal regulations. The action follows an October 2009 statement by Commissioner of Food and Drugs, Margaret Hamburg, M.D., encouraging companies to review their labeling to ensure that they are in compliance with FDA regulations...

FDA Accepts Biodel’s New Drug Application for Review

Biodel Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's new drug application seeking approval to market VIAject(R) for the treatment of diabetes. VIAject(R) is Biodel's proprietary formulation of recombinant human insulin that is designed to be absorbed into the blood faster than currently marketed rapid-acting insulin analogs...

First Governmental Lawsuit Against GSK Over Avandia

On Friday over its diabetes drug Avandia, charging a decade of false advertising and seeking compensation on behalf of patients and providers in California. MercuryNews reports the county claims the drugmaker made billions of dollars on Avandia, which caused heart attacks and strokes....

Gestational Diabetes Diagnosed at Lower Blood Glucose Levels

A new international study involving 23,000 women in nine countries suggests that more than twice as many mothers to be as previously thought will develop gestational diabetes. This finding is based on new measurements for determining dangerous blood sugar levels for the mother and her unborn baby. Previous guidelines to diagnose gestational diabetes were based on blood sugar levels that identified women...

Lilly and Amylin Confirm FDA Extension of Exenatide Once Weekly New Drug Application Review

The Food and Drug Administration (FDA) announced that following the closure of FDA building due to extreme weather it was granting a five day extension for the review of Amylin Pharmaceuticals Inc and Eli Lilly and Co's Exenatide Once Weekly New Drug Application. The new drug is part of a collaboration between the companies started in 2002, which includes the currently available twice daily type 2 diabetes drug...

GSK Rejects Allegation Regarding Avandia Safety

GlaxoSmithKline (GSK) responded to the recently released Senate Committee on Finance report regarding Avandia. GSK said it rejects any allegations of concealing safety information or acting inappropriately on behalf of patients. GSK also said it disagrees with the Committee’s decision to publish a Staff Report with the errors of fact, omissions, and inferences detailed in GSK’s White Paper....

Amylin and Takeda Advance Development of New Obesity Treatment

Amylin Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited announced that following positive phase 2 study results in a new obesity treatment, they will advance towards phase 3 development of a combination treatment for obesity which includes pramlintide (an analog of the natural hormone amylin) and metreleptin (an analog of the natural hormone leptin)...

IOM Report Declares High Blood Pressure a Neglected Disease

According to a new report by the Institute Of Medicine, high blood pressure is a neglected disease in the United States. The report calls for strategies to change Americans' lifestyles and diets to curb hypertension. High blood pressure or hypertension is easily preventable through diet, exercise and drugs, yet it is the second-leading cause of death in the United States, said committee chair.